This excerpt taken from the ELN 6-K filed Aug 28, 2009.
5 OTHER CHARGES
For the first half of 2009, included within cost of sales, SG&A expenses, and R&D expenses were total other charges of $40.6 million (2008: $5.6 million) consisting of the following:
During the first half of 2009, we incurred severance, restructuring and asset impairment charges of $40.6 million which were principally associated with the postponement of our biologics manufacturing activities, the strategic redesign and realignment of the R&D organisation within our Biopharmaceuticals business, and reduction of related support activities. These adjustments resulted in a reduction in our global workforce of approximately 230 positions, or 14% of our total workforce.
During the first half of 2008, we incurred severance, restructuring and other costs of $5.6 million arising principally from the 2007 site consolidation in our U.S. west coast operations and the restructuring of our commercial infrastructure which resulted in the closure of the San Diego facility and the expansion of our operations in South San Francisco. The restructuring of our commercial infrastructure was primarily a result of the approval of a generic form of Maxipime and the anticipated approval of a generic form of Azactam.
This excerpt taken from the ELN 6-K filed Mar 30, 2009.
During 2007, we incurred severance, restructuring and other costs of $3.8 million, $0.2 million included within cost of sales and $3.6 million included within SG&A, arising from the realignment of our resources to meet our business structure at that time.